1. Home
  2. ALXO vs SCWO Comparison

ALXO vs SCWO Comparison

Compare ALXO & SCWO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALXO
  • SCWO
  • Stock Information
  • Founded
  • ALXO 2015
  • SCWO 2021
  • Country
  • ALXO United States
  • SCWO United States
  • Employees
  • ALXO N/A
  • SCWO N/A
  • Industry
  • ALXO Biotechnology: Pharmaceutical Preparations
  • SCWO Environmental Services
  • Sector
  • ALXO Health Care
  • SCWO Utilities
  • Exchange
  • ALXO Nasdaq
  • SCWO Nasdaq
  • Market Cap
  • ALXO 58.9M
  • SCWO 58.8M
  • IPO Year
  • ALXO 2020
  • SCWO N/A
  • Fundamental
  • Price
  • ALXO $1.06
  • SCWO $0.40
  • Analyst Decision
  • ALXO Strong Buy
  • SCWO
  • Analyst Count
  • ALXO 6
  • SCWO 0
  • Target Price
  • ALXO $3.30
  • SCWO N/A
  • AVG Volume (30 Days)
  • ALXO 1.7M
  • SCWO 1.1M
  • Earning Date
  • ALXO 11-06-2025
  • SCWO 11-12-2025
  • Dividend Yield
  • ALXO N/A
  • SCWO N/A
  • EPS Growth
  • ALXO N/A
  • SCWO N/A
  • EPS
  • ALXO N/A
  • SCWO N/A
  • Revenue
  • ALXO N/A
  • SCWO $1,231,413.00
  • Revenue This Year
  • ALXO N/A
  • SCWO $5,945.19
  • Revenue Next Year
  • ALXO N/A
  • SCWO $106.82
  • P/E Ratio
  • ALXO N/A
  • SCWO N/A
  • Revenue Growth
  • ALXO N/A
  • SCWO 403.17
  • 52 Week Low
  • ALXO $0.40
  • SCWO $0.16
  • 52 Week High
  • ALXO $2.36
  • SCWO $1.99
  • Technical
  • Relative Strength Index (RSI)
  • ALXO 54.74
  • SCWO 69.37
  • Support Level
  • ALXO $1.06
  • SCWO $0.37
  • Resistance Level
  • ALXO $1.27
  • SCWO $0.43
  • Average True Range (ATR)
  • ALXO 0.12
  • SCWO 0.05
  • MACD
  • ALXO -0.02
  • SCWO 0.01
  • Stochastic Oscillator
  • ALXO 32.26
  • SCWO 85.79

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

About SCWO 374Water Inc.

374Water Inc offers a technology that transforms wet wastes such as sewage sludge, biosolids, food waste, hazardous and non-hazardous waste, and forever chemicals (e.g., PFAS) into recoverable resources by focusing on waste as a valuable resource for water, energy, and minerals. The company's business activities include manufacturing processes and waste recycling and treatment processes, which currently involve the use, treatment, storage, transfer, handling and/or disposal of hazardous materials, chemicals and wastes.

Share on Social Networks: